lymphoma

[Haematologica] By implementing pharmacogenomics and a cell-based drug screen, scientists found that THZ531 led to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro.

[Haematologica] Using diffuse large B cell lymphoma cell line models, the authors demonstrated the tumor suppressor activity of Germinal Center Proliferative Adapter RNA (GECPAR), which was mediated via its transcriptional regulation of proliferation and differentiation genes, particularly MYC and the Wnt pathways.

[HUYABIO InternationalTM (PR Newswire, Inc.)] HUYABIO International™ announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency. The drug was approved based on data from a Phase IIb study that involved 23 patients with aggressive ATL in Japan.

[Journal of Clinical Oncology] Investigators conducted a pilot clinical trial of a humanized CD19 CAR T-cell product in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia or B-lymphoblastic lymphoma, treated in two cohorts: with or without prior CAR exposure.

[Immunity] Researchers examined the effect of B cell stimuli on lymphoid stromal cells in follicular lymphoma (FL). FL B cells interacted primarily with CD49a+ fibroblastic reticular cells.

[Cancer Gene Therapy] Scientists made a comprehensive review on the outcomes resulted from the combination of CAR T-cell immunotherapy and oncolytic virotherapy for the treatment of solid cancers.